PIH11 ECONOMIC EVALUATION OF OSPEMIFENE FOR THE TREATMENT OF VULVOVAGINAL ATROPHY IN THE UNITED KINGDOM

To establish the cost-effectiveness of ospemifene, a selective oestrogen receptor modulator (SERM), for the treatment of post-menopausal women with moderate to severe symptomatic vulvovaginal atrophy (VVA) who are not candidates for local oestrogen therapy. The cost-effectiveness analysis included two treatment arms: ospemifene plus standard of care (SoC) (lubricants and moisturisers) and SoC alone. A cohort-based model including four health...